Radiotherapy is a widely used treatment for localized malignancies that is often delivered in combination with cytotoxic chemotherapeutic agents. The concept that treatment of localized tumors can be improved with a radio-and chemo-inducible gene therapy strategy has been investigated in the laboratory and now translated to the clinic. The TNFerade (Ad.Egr-TNF11D) adenoviral vector was engineered by inserting radio-and chemo-inducible elements from the Egr-1 promoter upstream to a cDNA encoding tumor necrosis factor-a (TNF-a). Transduction of tumor cells with TNFerade and then treatment with radiation or chemotherapy is associated with spatial and temporal control of TNF-a secretion and enhanced antitumor activity. TNFerade has been evaluated in trials for patients with sarcomas, melanomas and cancers of the pancreas, esophagus, rectum and head and neck. If the ongoing phase III trial for pancreatic cancer is successful, TNFerade will likely become the first gene therapy approved for cancer in the United States.
Introduction
Radiotherapy is primarily used to treat local and regional cancers. Ionizing radiation (IR) is highly effective against small (o2 cm) tumors, but is relatively ineffective when used as a single modality in the treatment of locally advanced larger tumors. In addition, IR is ineffective against specifically resistant histological tumor types, such as pancreatic cancer and glioblastoma. In locally advanced (T3-T4) tumors, radiotherapy is therefore frequently used in combination with surgery and/or chemotherapy. These combination strategies have been found to be effective in preserving function, enhancing cosmetic results and improving survival, for example, in patients with head and neck, cervix and anal cancer. However, chemotherapy, radiotherapy and surgery can have significant toxicities that decrease the therapeutic index of the combined treatments. In many tumor types, which include brain, lung and esophageal cancers, only modest improvements in survival have been achieved with combined modality treatment. Research in the field of radiotherapy has been focused on delivering increased doses of IR to the tumor relative to the normal tissues (for example, intensity-modulated radiotherapy and proton radiotherapy). Other investigative strategies have included the frequency of radiation delivery (twice a day radiotherapy as compared with conventional radiotherapy delivered once per day) and very large single doses (o15 Gy) in 'radiosurgery' approaches. These strategies have been associated with some improvement in outcomes; however, the effects of these altered fractionation schemes have been relatively small in terms of increased cure rates. Innovations based on current advances in biology have only begun to be applied to radiotherapy. One approach, gene therapy, has had relatively limited laboratory investigation with IR and has been applied to radiotherapy in few clinical trials. This review will focus on the development of TNFerade (Ad.Egr-TNF11D), a radio-and chemo-inducible gene therapy vector, for improving outcomes in cancer treatment. TNFerade was engineered by inserting elements from the early growth response gene 1 (Egr-1) promoter upstream to a cDNA encoding human tumor necrosis factor-a (TNF-a) and is now in advanced clinical testing. 1, 2 Development of the concept that radiotherapy can confer spatial and temporal control of gene therapy Radiotherapy is generally delivered to a specific target/ tumor volume that encompasses the tumor and a margin for error. Unlike chemotherapy, the effects of IR are dependent on temporal and spatial delivery.
Weichselbaum et al. 3 proposed the concept of utilizing a radiation-inducible promoter linked to a toxin that would be activated by radiotherapy only in the tumor and thereby spare normal tissues. This concept of radiotherapy controlled gene therapy was validated in the laboratory and in animal models, and then translated to clinical trials by the GenVec Corporation. The initial laboratory studies were carried out with radio-inducible CC(A þ T rich)GG (CArG) elements from the Egr-1 promoter 4,5 ligated upstream to a cDNA encoding human TNF-a 6 ( Figure 1 ). This chimeric construct was cloned into an adenovirus type 5, which was rendered replication defective by deletion of the E1 and E3 genes (Ad.Egr-TNF). 7 Ad.Egr-TNF was used in most of the laboratory investigations before 2000; however, a second-generation vector with deletion of the E1, E3 and E4 genes was subsequently produced for clinical trials and is referred to as TNFerade. Ad.Egr-TNF and TNFerade are comparable in terms of antitumor activity in preclinical models and are used interchangeably in this review.
The CArG sequences of the Egr-1 promoter: a trigger for radiation-activated gene therapy
The concept that radiation could be used to regulate gene therapy emerged, in part, from the finding that IR induces transcription of the TNF-a gene. 8 Activation of mammalian gene expression by IR was confirmed in subsequent studies, particularly with induction of the c-jun 9 and Egr-1 4 early response genes. Other work confirmed that the Egr-1 gene is induced by IR in diverse rodent and human tumor cell lines and in tumor xenografts. 6, 10 Activation of the Egr-1 gene in irradiated human A375 melanoma cells was reported to confer the growthinhibitory response to radiation. 11 However, in contrast, inducibility of Egr-1 expression by IR has been implicated in the repair of sublethal and potentially lethal radiation damage. 12 Thus, activation of Egr-1 expression would appear to have different functional consequences that are dependent on cell context. Deletion analysis of the Egr-1 promoter identified a region containing six serum-responsive CArG elements as the sequences responsible for IR-induced activation (Figure 1) . These experiments were carried out by ligating Egr-1 promoter constructs upstream to a CAT reporter gene. Importantly, the finding that CArG elements are sufficient to confer radioinducibility using an HSV-TK minimal promoter supported the general applicability of using the CArG sequences for activating heterologous genes. 4 In addition, activation of the Egr-1 promoter and specifically the CArG elements has been shown over a broad range of IR doses and also in the response to radioisotopes, neutrons and photons. 6, 7, [13] [14] [15] [16] [17] The demonstration that IR-induced activation of the CArG elements is blocked by antioxidants supported the generation of reactive oxygen species (ROS), rather than direct damage to DNA, as the upstream signal 5 ( Figure 1 ). However, other studies have indicated that activation of the Egr-1 promoter in the IR response is mediated, in part, by the release of a diffusible factor into the culture medium. 18 The CArG elements in the Egr-1 promoter have been modified to improve radio-inducibility. Increasing the number of CArG motifs and altering the A/T ratio in these sequences enhanced induction two-to three-fold. 19 In another strategy, hypoxia-responsive elements from the erythropoietin gene and others have been combined with CArG elements to enhance radio-induction of heterologous genes in hypoxic tumors. [20] [21] [22] [23] These and other findings outlined above have collectively supported the CArG sequences as the prototype for a molecular switch in radiation-activated gene therapy.
The CArG elements in the EGR-1 promoter are also activated in the response to cytotoxic chemotherapy
The available evidence indicates that the CArG elements are activated in the response to DNA damage and the formation of ROS. As found with IR, treatment with certain genotoxic anticancer agents is also associated with ROS production. 1, 2, 24, 25 In this context, human esophageal and rat colon cancer cells transduced with Ad.Egr-TNF responded to cisplatin treatment with activation of the vector. 26 Other studies showed that the CArG sequences are activated by 5-fluorouracil (5FU), gemcitabine, paclitaxel, doxorubicin, cyclophosphamide and temozolomide, indicating that this response is mediated by diverse types of DNA damage. 14, 24, 27 Importantly and as shown with IR, the finding that activation of the CArG sequences by chemotherapeutic agents is abrogated by antioxidants has supported a response that is conferred by genotoxic stress and thereby the generation of ROS. 24 In Figure 1 Activation of the Egr-TNF construct by IR and chemotherapy. The Egr-TNF construct was generated by inserting six radio-and chemo-inducible CArG elements from the Egr-1 gene promoter upstream to a cDNA encoding TNF-a. Transduction of tumor cells with the Ad.Egr-TNF adenovector and then treatment with radiation or chemotherapy activates the CArG elements by a mechanism dependent in large part on the generation of reactive oxygen species. In turn, transcription of the TNF-a cDNA is associated with secretion of TNF-a into the tumor microenvironment at high local concentrations. The effects of TNF-a on the tumor vasculature and on the synergistic interaction of TNF-a with radiation and chemotherapy against tumor cells results in increased antitumor activity.
this regard, radiation is often combined with chemotherapy and the induction of similar DNA damage-ROS pathways could contribute to the activation of Ad.Egr-TNF. The preclinical applications of radio-and chemoinducible gene therapy will be further developed below.
TNF-a: the cytotoxic arm of the radio-and chemo-inducible Ad.Egr-TNF vector
Translation of the finding that CArG elements can be used to drive transcription in response to radiation and chemotherapy necessitated the identification of an exogenous gene that would be activated by this approach. Selection of the exogenous gene was based on the need for one that encodes a diffusible factor with antitumor activity and the potential for enhancing the effects of radiotherapy and/or chemotherapy. The TNF-a gene fulfilled these criteria. TNF-a is a pleotropic cytokine that is of importance to the regulation of immunity, inflammation, cell proliferation and apoptosis; 28 it is expressed as secreted (sTNF-a) and transmembranebound (tmTNF-a) forms. 29 Transmembrane TNF-a is anchored by a leader sequence that is cleaved by the TNFa-converting enzyme (TACE/ADAM17) to release sTNFa. The effects sTNF-a are conferred by activation of two receptors, TNF receptor 1 (TNF-R1, p55kd) and TNF receptor 2 (TNF-R2, p75kd). The cytotoxic antitumor activity of TNF-a is predominantly mediated by TNF-R1, whereas TNF-R2 signals primarily in cells of the immune system. The sTNF-a and tmTNF-a forms have similar actions, although tmTNF-a interacts with TNFRs through cell-cell contacts. 30 Cells expressing tmTNF-a can also undergo reverse signaling by activation of membrane or soluble TNFRs. 31 Moreover, after TACE cleavage, tmTNF-a is subject to further processing by signal peptide peptidases with release of the TNF-a intracellular domain and its translocation to the nucleus.
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TNF-a-mediated cell death
Stimulation of TNF-R1 by TNF-a induces the formation of a complex with the adapter TNF receptor-associated death domain (TRADD), TNF receptor-associated factor 2 (TRAF2) and receptor-interacting protein 1 (RIP1), and thereby activation of nuclear factor-kB (NF-kB) and cell survival 34 ( Figure 2 ). In an alternative signaling pathway, TRADD and RIP1 associate with Fas-associated death domain (FADD) and caspase-8. 34, 35 Activation of caspase-8 results in the cleavage of pro-caspase-3 and the induction of apoptosis [36] [37] [38] ( Figure 2 ). NF-kB induces expression of the long form of the caspase-8 (FLICE)-like inhibitory protein (cFLIPL) that blocks activation of caspase-8 and the apoptotic response ( Figure 2 ). Other NF-kB-dependent genes encode anti-apoptotic proteins, such as X-linked inhibitor of apoptosis protein (XIAP), cIAP, Bcl-2 and Bcl-xL, that also block TNF-a-induced death 39, 40 ( Figure 2 ). Although TNF-a commonly induces apoptotic death, this cytokine can also induce a nonapoptotic caspase-independent necrotic death mediated by free radicals and changes in cellular redox status. [41] [42] [43] TNF-a induces death of certain human tumor cells and, importantly, enhances the effects of IR and chemotherapeutic agents. 44, 45 Conversely, TNF-a can also mediate tumor cell survival and resistance to genotoxic stress by activating NF-kB. 46 Thus, the cytotoxic effects of TNF-a are not uniform, and cytoprotection can occur in some tumor cells and normal tissues when TNF-a is combined with DNA-damaging agents. For example, the bone marrow is protected from IR killing by TNF-a, probably by activating NF-kB and thereby expression of the radical scavenger, manganous superoxide dismutase. 47, 48 Also, protein synthesis inhibitors are necessary for TNF-ainduced death of certain tumor cells, presumably to inhibit transcription of NF-kB-dependent survival genes.
TNF-a-mediated anti-tumor effects
TNF-a derives its name from the observation that, in experimental murine tumors, regression induced by systemic TNF-a administration occurs as a consequence of tumor necrosis. The induction of tumor necrosis by TNF-a is attributed, at least in part, to the activation of a Figure 2 TNF-a-mediated activation of survival and apoptotic pathways. Activation of TNF-R1 by TNF-a induces the formation of a complex with TRADD, TRAF2 and RIP1 that, in turn, results in the activation of NF-kB and survival. 34 Alternatively, TRADD and RIP1 recruit FADD with activation of caspase-8 and the induction of apoptosis. NF-kB activates the expression of cFLIP and other antiapoptotic proteins that suppress the caspase-8 activation pathway.
procoagulation environment within the tumor vasculature that contributes to thrombosis. 49, 50 Tumor necrosis has also been reported in the presence of anticoagulants and, thus, it is unclear whether tumor vessel thrombi are a cause or consequence of destruction of the proliferating tumor-associated endothelium. Upregulation of integrins, for example, alphaV/beta3, has been reported after TNF-a administration in humans and animals, which in turn enhances the antiangiogenic effects of TNF-a and may, in part, contribute to thrombosis in the tumor vasculature. 51 The dramatic antitumor effects in response to systemic administration of TNF-a in animals inspired human clinical trials. However, the systemic administration of TNF-a to patients was abandoned because of toxicity. 52, 53 The clinical use of TNF-a in cancer therapy is thus currently restricted to local tumor arterial perfusion, whereby arteries of the extremities of patients with locally advanced recurrent melanoma with 'in transit' cutaneous metastasis or soft tissue sarcoma are perfused with TNF-a and the induction of tumor necrosis is associated with excellent palliative results. 51 Although the clinical data with TNF-a support a vascular mechanism, the finding that combining TNF-a with smallmolecule inhibitors of XIAP increases tumor cell killing in vitro has reignited interest in the direct targeting of tumor cells. 54 Preclinical data with Ad.Egr-TNF and radiation therapy
The systemic delivery of low TNF-a doses in combination with radiotherapy provided evidence that TNF-a is a potent radiosensitizer. 55 Although this clinical approach was also abandoned because of toxicity, the findings inspired investigation of gene therapy strategies to localize TNF-a within tumor sites and thereby limit systemic toxicity. In initial proof of concept experiments, the chimeric Egr-1 promoter (CArGx6)-TNF-a construct was transfected into HL525 leukemia cells as a delivery vehicle. The HL525/Egr-TNF cells were injected into a tumor xenograft of radioresistant human SQ20B squamous carcinoma cells. Significantly, the SQ20B tumors injected with HL525/Egr-TNF cells were more responsive to radiation therapy in terms of regression than the controls. 6, 7 To translate this strategy to a clinically applicable approach, the Egr-TNF cassette was integrated into a replication-defective adenoviral vector with deletions of the E1 and E3 genes (Ad.Egr-TNF). The Ad.Egr-TNF vector was injected into SQ20B tumors. Importantly, the combination of Ad.Egr-TNF and IR produced superior tumor regression as compared with groups of animals treated with Ad.Egr-TNF or IR alone. 7 Moreover, intratumoral human TNF-a was induced approximately eight-fold in tumors injected with Ad.Egr-TNF and treated with 500 cGy IR delivered in 10 treatments. These findings validated the concept of spatial and temporal control of gene therapy by fractionated radiotherapy.
Treatment of SQ20B xenografts with Ad.Egr-TNF and IR was associated with thrombosis in the tumor-associated vasculature (Figure 3) , which was not observed in blood vessels in the adjacent normal muscle or after direct injection of Ad.Egr-TNF and irradiation of normal muscle. 56 The thrombotic vascular effects of Ad.Egr-TNF in combination with IR were also found in a human U87 glioma xenograft model. 57 These findings, considered together with the effects of infusing TNF-a in humans, supported the concept of a TNF-a-induced protocoagulant microenvironment in the tumor leading to vascular thrombosis and subsequent tumor necrosis. These findings are also consistent with relatively minor toxicities observed in tumor-bearing mice treated with Ad.Egr-TNF and IR when compared with those found for treatment with the Ad.Egr-TNF vector alone or IR alone. Injection of Ad.EGR-TNF into the normal muscle and then activated by IR was associated with only mild fibrosis and no vascular abnormalities, further indicating that proliferating endothelial cells are a target of this therapy. The efficacy of Ad.Egr-TNF and IR has been shown in preclinical models of human and murine epidermoid carcinoma of the head and neck, glioma, esophageal carcinoma, prostate cancer and melanoma. 57, 58 Preclinical data with Ad.Egr-TNF and cytotoxic chemotherapeutic agents TNF-a has been combined with several chemotherapeutic agents to enhance killing of tumor cells in vitro. 44, 59, 60 In animal models, TNF-a increases drug delivery to tumors by increasing tumor vascular permeability, remodeling the cytoskeleton and by rearranging the adhesion molecules, platelet-endothelial cell adhesion molecule-1 (PECAM-1) and E-cadherin. 51 To determine whether Ad.Egr-TNF could be effectively combined with chemotherapy in a preclinical model, cisplatin was administered to activate Ad.Egr-TNF transduced into human esophageal carcinoma and rat colon cancer cell xenografts. 26 Significant induction of human TNF-a and enhanced regressions were found in the tumors treated with Ad.Egr-TNF and cisplatin. In other animal models, resistance of both human and rodent xenografts to doxorubicin was reversed by tranducing tumor cells with Ad.Egr-TNF and then treating with doxorubicin. 24 In contrast to doxorubicin, temozolamide is a monofunctional alkylating agent used in the treatment of glioblastoma. Activation of Ad.Egr-TNF in human U87 glioblastoma xenografts by temozolomide was associated with synergistic regression of these tumors compared with either treatment alone. 61 Moreover, the combination of Ad.Egr-TNF, temozolomide and IR resulted in further enhancement of tumor regression. 61 Stromal host factors as a target for Ad.Egr-TNF An important controversy has arisen over whether the tumor or tumor-associated stroma is a principal target of radiotherapy and radiosensitization. In this context, we investigated whether the combination of Ad.Egr-TNF and IR exerts antitumor effects on tumor cells or the tumor-associated stroma. To examine tumor-stromal interactions, we studied animal models with host stromal tissues that are resistant to the effects of TNF-a because of germline deletions of TNF-R1 or of TNF-R1 and TNF-R2. 62 B16 melanoma tumors were established in wild-type and TNF-R1 À/À or TNF-R1/2 À/À mice. Treatment with Ad.Egr-TNF and IR resulted in greater B16 tumor regressions in wild-type animals as compared with that in TNF-R1 À/À or TNF-R1/2 À/À mice. An increase in endothelial cell apoptosis was also observed in the B16 tumors established in wild-type mice, but not in the TNF-R1 À/À or TNF-R1/2 À/À mice. These findings indicated that the response to Ad.Egr-TNF and IR is dependent, at least in part, on the tumor vasculature. 62 Silencing TNF-R1 expression in the B16 melanoma cells with a small interfering RNA had no effect of this response, further supporting dependence on the tumor stroma, specifically the tumor endothelium, for radiosensitization by TNF-amediated gene therapy. 62 Studies were also carried out to determine whether treatment with Ad.Egr-TNF and IR has effects on metastasis. To address this issue, B16 tumors were treated with 4 Gy IR alone or Ad.Egr-TNF and 2 Gy IR (to achieve equal cell kill in the primary B16 flank tumor). Inguinal and iliac lymph node metastases were suppressed with Ad.Egr-TNF and IR as compared with those found with 4 Gy alone or vector alone. Moreover, metastases were observed in TNF-R1 À/À mice, indicating that a stromal response to TNF-a is necessary for the antimetastatic effect. Activation of Ad.Egr-TNF by IR could function locally to reduce the metastatic process by a reduction or delay in the egress of tumor cells from the primary tumor, for example, by inducing changes in cytokine receptors on tumor cells. Another possibility is that Ad.Egr-TNF and IR have an impact on the mode of dissemination (for example, hematogenous vs lymphatic). Finally, the results could be due to the effects of TNF-a on induction of an immune response against the tumor cells. 63 Effects of TNF-a on antitumor immunity TNF-a has been linked to antitumor immunity as a cytotoxic effector that is secreted by macrophages and natural killer cells. 64, 65 TNF-a also interacts with other cytokines in the maturation of dendritic cells, is essential for modulating thresholds for activation and tolerance of CD8 þ cells and increases major histocompatibility complex (MHC) class I expression. 31 A recent report has further showed that, although granzyme and perforin are important for direct killing of tumor cells by cytotoxic T cells, TNF-a and interferon-g are of importance for destruction of the tumor stroma and essential for immune activation to achieve cures in experimental tumor systems. 66 Moreover, some of the antivascular effects of TNF-a may be mediated by an immune mechanism. 67 
Effects of radiation on the immune system
Whole-body or total nodal irradiation is generally immunosuppressive; however, focal irradiation of tumors can enhance antitumor immunity. In this context, cell surface expression of MHC class I molecules is increased for days in a radiation dose-dependent manner. 68 Local radiation of tumors is also associated with enhanced degradation of existing proteins and thereby an increased intracellular peptide pool for antigen presentation. 68 Moreover, radiation activates the mammalian target of rapamycin pathway, enhances translation and thereby increases peptide production, antigen presentation and cytotoxic T lymphocyte recognition of irradiated cells. 68 Other studies have shown that treating established tumors with local irradiation is associated with the release of antigen and sensitization of stromal cells with the destruction by cytotoxic T lymphocytes. 66 This response was confirmed directly using high-affinity T-cell receptor tetramers for assessing the transient appearance of tumorspecific peptide-MHC complexes on stromal cells. Maximum loading of tumor stroma with antigen occurred 2 days after irradiation and coincided with the optimal time for T-cell transfer. Breaking down the tumor stroma barrier by radiation could thus allow for better antigen presentation to dendritic cells, elaboration of 'danger signals' (for example, high-mobility group box protein 1) and greater access to cytotoxic T cells for attack of the tumor. These findings indicate that the combination of Ad.Egr-TNF and IR as local tumor treatment could contribute to disruption of the tumor stroma and induction of antitumor immunity against both local and distant sites of disease.
Clinical trials with Ad.Egr-TNF (TNFerade) and radiotherapy
In the initial phase I trial of TNFerade and radiotherapy, 36 patients were evaluated for toxicity and 30 patients for clinical response. 69 Tumors were injected locally with TNFerade at doses ranging from 4 Â 10 7 to 4 Â 10 11 p.f.u. and were treated with IR ranging from 30 to 70 Gy. Adverse effects attributable to TNFerade were reported in B20% of patients and included fever, pain at the injection site and chills. No dose-limiting toxicities were observed. Of 30 patients, 21 had responses or stable disease. Five patients achieved a complete response. Of particular interest, three of five patients who achieved complete responses had melanoma metastatic to regional nodes, and all three of these patients survived over at least 3 years. TNFerade was considered safe and of interest for further clinical evaluation. 69 A second phase I trial of TNFerade and IR was carried out on 14 patients with locally advanced or metastatic soft tissue sarcoma. Patients received 4 Â 10 9 -4 Â 10 11 p.f.u. and 36-50 Gy IR. No dose-limiting toxicities were observed; however, fever and chills were observed in 50 and 43% of patients, respectively. Of 13 patients, 11 had objective tumor responses. Eleven patients underwent surgical resection and 10 had complete (2) or partial responses (8) pathologically. Four of the eight partial pathological responses exhibited o95% necrosis. All 11 patients had negative margins. There was a discrepancy in response as measured by computerized tomography (CT), and pathological evaluation after resection in that CT dramatically underestimated pathological response. These results suggested that TNFerade could be safely administered in patients with locally advanced soft tissue sarcoma and that significant antitumor effects could be achieved in patients with large tumors. 70 These findings also indicate that TNFerade and IR may be an excellent and less toxic alternative to limb perfusion for patients with advanced melanoma and sarcoma.
Clinical trials with TNFerade, radiotherapy and chemotherapy
Esophageal carcinoma
Patients with nonmetastatic locally advanced esophageal cancer were treated with TNFerade in combination with both chemotherapy and radiotherapy. 71, 72 Patients (24) received TNFerade at 4 Â 10 9 -4 Â 10 11 p.f.u. through direct tumor injection using intra-esophageal ultrasound or conventional endoscopy. Patients received concurrent 5FU, cisplatin and radiotherapy (45 Gy: 1.8 Gy/day/5 weeks). Of 19 patients, who underwent subsequent resection, 6 had achieved a complete pathological response. One patient was medically inoperable, one patient died prior to resection and one patient was not resectable at exploration. Of concern was that one patient died of a pulmonary embolism and three additional patients developed pulmonary emboli. It is notable that 48.4% of patients remained alive at 5 years ( Figure 4) . By contrast, most randomized trials for the treatment of locally advanced esophageal cancer report survival rates of 12-18 months [73] [74] [75] [76] (Figure 4 ).
Pancreatic cancer
TNFerade was studied in patients with locally advanced nonmetastatic pancreatic cancer. In a phase I-II trial, TNFerade was injected at doses of 4 Â 10 9 , 4Â 10 10 , 4 Â 10 11 and 1 Â 10 12 p.f.u. directly into the pancreatic cancers through endoscopic ultrasound or percutaneous CT guided delivery concurrently with IR (50 Gy: 45 Gy þ 5 Gy boost) and infusional 5FU. [77] [78] [79] [80] Toxicities were flu-like symptoms and a deep vein thrombosis noted at 4 Â 10 9 -4 Â 10 11 p.f.u. TNFerade. At 1 Â 10 12 p.f.u. TNFerade, two dose limiting toxicities (DLTs) were noted including pancreatitis and billiary obstruction, as well as renal insufficiency. The MTD was thus designated as 4 Â 10 11 p.f.u. TNFerade. A dose-dependent increase in survival was observed with 4 Â 10 11 p.f.u. TNFerade as compared with the lower doses ( Figure 5 ). In addition, 5 of 11 patients treated with 4 Â 10 11 p.f.u. TNFerade became resectable and 4 of those patients had negative margins. On the basis of these results, a phase III randomized trial was initiated, in which treatment with 5FU and 50 Gy IR (standard of care; SOC) is being compared with TNFerade in combination with 5FU and 50 Gy. Adjuvant gemcitabine or gemcitabine and erlotinib were allowed for all patients after definitive treatment. Safety was analyzed after treatment of the first 51 patients. 81, 82 TNFerade and SOC were associated with higher rates of low-grade fevers (58%) and chills (52%) relative to SOC alone (22 and 6% fevers and chills, respectively). No other significant differences in toxicities were noted. In an interim analysis after 92 deaths, the 12 month survival in the TNFerade, chemotherapy and radiotherapy group was approximately 40% versus approximately 20% in the control group (P ¼ 0.16). 
Future directions and potential modifications to improve TNFerade
The clinical results with TNFerade are provocative, particularly in the difficult-to-treat human cancers. However, some patients do not respond to TNFerade treatment, and there are several areas of investigation that might potentially lead to improvement with this agent.
Investigation into mechanisms of TNFerade resistance
On the basis of data with TNFerade, IR and chemotherapy, it appears likely that the stromal effects dominate the response of tumors to these combination treatments. However, it is unknown whether the stroma differs from patient to patient within histologically similar tumors and thereby confers resistance. Therefore, understanding the contributions of the stroma to the tumor could help overcome potential resistance to TNFerade. For example, sensitivity to the TNFerade and IR combination could relate to differential expression of survival genes or proliferation rates of the tumor-associated endothelium. Cytokines or other soluble factors secreted by the tumor could also determine response of the tumor endothelium to the activation of TNFerade in the response to IR and chemotherapy. In this setting, the combination of TNFerade and chemo-radiotherapy with an angiogenesis inhibitor might be more effective than treatment with TNFerade and chemo-radiotherapy.
Tumor cells have received less emphasis than stroma in TNF-a-mediated cytotoxicity. However, if tumor cells can be sensitized to IR or chemotherapy with high local concentrations of TNF-a, it could be possible to lower the therapeutic threshold 'below' that of the stroma. Recent reports of using small-molecule inhibitors of XIAP to directly enhance TNF-a killing of tumor cells might facilitate such a strategy and increase sensitization of both tumor cell and stromal elements. 54 Improve the cytotoxic index of TNFerade by inhibiting NF-kB NF-kB is induced by TNF-a, IR and certain chemotherapeutic agents, and mediates resistance to killing by activation of NF-kB target genes. As noted above for an experimental brain tumor model, temozolamide enhances the antitumor effects of TNFerade and IR, in part, by inhibiting NF-kB activation. These results indicate that inhibitors of NF-kB signaling that are under development could be effective in combination with TNFerade-based therapeutic approaches.
Improve the immune index of TNFerade TNF-a and radiation induce complementary antitumor immune effects in terms of MHC class 1 presentation, T-cell activation and presentation of peptides to dendritic cells. Technical modifications in radiotherapy could enhance TNFerade-induced antitumor immunity by, for example, avoiding the draining tumor lymph nodes where dendritic cells present antigens to T cells. The draining nodes could be treated with radiation several weeks later. The use of additional cytokines, such as interferon, LIGHT and interleukin-12 could also enhance the antitumor immunity of TNF-a and IR. Although activation of antitumor immunity by TNFerade in combination with radiation and chemotherapy is speculative at this point, the apparent increase in survival of patients with pancreatic and esophageal cancer suggests that antitumor immunity may indeed be induced by TNFerade. If future results support such an immune-mediated mechanism, one could envisage using TNFerade in combination with administration of antitumor vaccines. Adaptive image guided application of TNFerade A limitation of a locally administered gene therapy is that it is difficult to ensure uniform distribution of vector and the secreted cytokine. An advantage of local administration is that subsequent injections can compensate for areas within the tumor that were not targeted initially. Imaging areas of adenovirus infection is difficult; however, it might be possible to image the effects of TNFerade. Our preliminary data suggest that TNFerade and IR induce measurable areas of hypoxia as assessed by magnetic resonance imaging and electron-spin resonance spectroscopy. The use of magnetic resonance imaging and electron-spin resonance spectroscopy should guide where subsequent doses of TNFerade should be delivered within the tumor. Also, information on the oxygenation status of the tumor could indicate optimal timing for subsequent doses of TNFerade and IR, which presumably should be carried out in normoxic conditions. Radiotherapy and certain chemotherapeutic agents require oxygen for maximal effectiveness, and TNF-a may have a similar dependence in the induction of cell death through ROS production. Thus, image guidance can assist in optimizing both spatial and temporal administration of the combination of TNFerade, IR and chemotherapy.
Improved adenovectors to target tumors
Chemo-inducible TNFerade is likely to be used for tumors that can be injected locally and have a local component of failure (for example, brain tumors). One broad application of TNFerade is potentially systemic administration and inducibility by chemotherapeutic agents. A limitation of the strategy has been the difficulty in targeting adenovectors to tumors after intravenous injection. There is a substantial literature on the subject and several excellent reviews focus on tumor targeting of systemically injected adenovectors. 84, 85 However, despite intensive research in systemic administration of these vectors, there has been little success in this area. Chemoinducibility should contribute to systemic efficacy in the next generation of systemically targeted adenovectors and would broaden the applicability of TNFerade.
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